Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Radiant Research - Atlanta
mi
from
Atlanta, GA
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Radiant Research - Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Springfield Clinic
mi
from
Springfield, IL
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Springfield Clinic
mi
from
Springfield, IL
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Kansas City Dermatology, PA
mi
from
Overland Park, KA
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Kansas City Dermatology, PA
mi
from
Overland Park, KA
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Derm Research, LLC
mi
from
Louisville, KY
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Derm Research, LLC
mi
from
Louisville, KY
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Hamzavi Dermatology Clinical Research
mi
from
Fort Gratiot, MI
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Hamzavi Dermatology Clinical Research
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Grekin Skin Institute
mi
from
Warren, MI
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Grekin Skin Institute
mi
from
Warren, MI
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Radiant Research - Edina
mi
from
Edina, MN
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Radiant Research - Edina
mi
from
Edina, MN
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Central Dermatology
mi
from
St. Louis, MO
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Central Dermatology
mi
from
St. Louis, MO
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Psoriasis Treatment Center of Central New Jersey
mi
from
East Windsor, NJ
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Psoriasis Treatment Center of Central New Jersey
mi
from
East Windsor, NJ
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Skin Search of Rochester, Inc
mi
from
Rochester, NY
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Skin Search of Rochester, Inc
mi
from
Rochester, NY
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
DermResearch Center of New York
mi
from
Stony Brook, NY
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
DermResearch Center of New York
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
PMG Research of Carey, LLC
mi
from
Cary, NC
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
PMG Research of Carey, LLC
mi
from
Cary, NC
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
DJL Clinical Research
mi
from
Charlotte, NC
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
DJL Clinical Research
mi
from
Charlotte, NC
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
PMG Research of Wilmington
mi
from
Wilmington, NC
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
PMG Research of Wilmington
mi
from
Wilmington, NC
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Radiant Research, Inc.
mi
from
Cincinnati, OH
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Radiant Research, Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Altoona Center for Clincal Research
mi
from
Duncansville, PA
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Altoona Center for Clincal Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Radiant Research - Anderson
mi
from
Anderson, SC
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Radiant Research - Anderson
mi
from
Anderson, SC
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Radient Research - Greer
mi
from
Greer, SC
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Radient Research - Greer
mi
from
Greer, SC
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Rivergate Dermatology
mi
from
Goodlettsville, TN
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Rivergate Dermatology
mi
from
Goodlettsville, TN
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Neighborhood Medical Center
mi
from
Dallas, TX
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Neighborhood Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Center for Clinical Studies
mi
from
Houston, TX
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Heights Dermatology & Aesthetic Center
mi
from
Houston, TX
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Heights Dermatology & Aesthetic Center
mi
from
Houston, TX
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Progressive Clinical Research - San Antonio
mi
from
San Antonio, TX
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Progressive Clinical Research - San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Center for Clinical Studies
mi
from
Webster, TX
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Center for Clinical Studies
mi
from
Webster, TX
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
DBA Dermatology Associates
mi
from
Seattle, WA
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
DBA Dermatology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Premier Clinical Research
mi
from
Spokane, WA
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Premier Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Mountain State Clinical Research
mi
from
Clarksburg, WV
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Mountain State Clinical Research
mi
from
Clarksburg, WV
Click here to add this to my saved trials
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated:  8/10/2015
Clinical Research Center of Reading, LLC
mi
from
Wyomissing, PA
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)
Status: Enrolling
Updated: 8/10/2015
Clinical Research Center of Reading, LLC
mi
from
Wyomissing, PA
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
1264.3.01019 Boehringer Ingelheim Investigational Site
mi
from
Port Orange, FL
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
1264.3.01019 Boehringer Ingelheim Investigational Site
mi
from
Port Orange, FL
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
1311.2.10003 Boehringer Ingelheim Investigational Site
mi
from
Arlington Hts, IL
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
1311.2.10003 Boehringer Ingelheim Investigational Site
mi
from
Arlington Hts, IL
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
1275.1.01026 Boehringer Ingelheim Investigational Site
mi
from
Bay City, MI
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
1275.1.01026 Boehringer Ingelheim Investigational Site
mi
from
Bay City, MI
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
205.452.01104 Boehringer Ingelheim Investigational Site
mi
from
Fridley, MN
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
205.452.01104 Boehringer Ingelheim Investigational Site
mi
from
Fridley, MN
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
1311.2.10001 Boehringer Ingelheim Investigational Site
mi
from
East Windsor, NJ
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
1311.2.10001 Boehringer Ingelheim Investigational Site
mi
from
East Windsor, NJ
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
1311.2.10009 Boehringer Ingelheim Investigational Site
mi
from
Verona, NJ
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
1311.2.10009 Boehringer Ingelheim Investigational Site
mi
from
Verona, NJ
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
1222.29.11003 Boehringer Ingelheim Investigational Site
mi
from
Raleigh, NC
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
1222.29.11003 Boehringer Ingelheim Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Portland, OR
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated:  8/12/2015
1311.2.20002 Boehringer Ingelheim Investigational Site
mi
from
Markham,
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Status: Enrolling
Updated: 8/12/2015
1311.2.20002 Boehringer Ingelheim Investigational Site
mi
from
Markham,
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Status: Enrolling
Updated:  8/14/2015
Coastal Clinical Research Inc
mi
from
Mobile, AL
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Status: Enrolling
Updated: 8/14/2015
Coastal Clinical Research Inc
mi
from
Mobile, AL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Status: Enrolling
Updated:  8/14/2015
Omni Dermatology
mi
from
Phoenix, AZ
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Status: Enrolling
Updated: 8/14/2015
Omni Dermatology
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Status: Enrolling
Updated:  8/14/2015
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Status: Enrolling
Updated: 8/14/2015
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Status: Enrolling
Updated:  8/14/2015
University Clinical Trials, Inc.
mi
from
San Diego, CA
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Status: Enrolling
Updated: 8/14/2015
University Clinical Trials, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials